{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:42:27Z","timestamp":1791859347074,"version":"4.3.4"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.591176","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T05:27:11Z","timestamp":1603258031000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies"],"prefix":"10.3389","volume":"11","author":[{"given":"Ariane","family":"Hammitzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Moog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis.","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/annrheumdis-2019-216841","article-title":"Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?","volume":"79","author":"Jones","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3899\/jrheum.170477","article-title":"Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: first-year response predicts longterm drug persistence.","volume":"45","author":"Flouri","year":"2018","journal-title":"J Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system.","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","article-title":"IL-17 in the immunopathogenesis of spondyloarthritis.","volume":"14","author":"Taams","year":"2018","journal-title":"Nat Rev Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.","volume":"168","author":"Parham","year":"2002","journal-title":"J Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","article-title":"Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs.","volume":"104","author":"Gadina","year":"2018","journal-title":"J Leukoc Biol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00885","article-title":"Whodunit? The contribution of interleukin (IL)-17\/IL-22-producing gammadelta T Cells, alphabeta T cells, and innate lymphoid cells to the pathogenesis of spondyloarthritis.","volume":"9","author":"Reinhardt","year":"2018","journal-title":"Front Immunol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02668","article-title":"The early phases of ankylosing spondylitis: emerging insights from clinical and basic science.","volume":"9","author":"Watad","year":"2018","journal-title":"Front Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention.","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.berh.2018.09.005","article-title":"Genetics in ankylosing spondylitis\u2013current state of the art and translation into clinical outcomes.","volume":"31","author":"Brown","year":"2017","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13242","article-title":"New developments in our understanding of ankylosing spondylitis pathogenesis.","author":"Voruganti","year":"2020","journal-title":"Immunology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/s1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1172\/JCI126567","article-title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis.","volume":"130","author":"Gracey","year":"2020","journal-title":"J Clin Invest."},{"key":"B15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells.","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides.","volume":"203","author":"Liang","year":"2006","journal-title":"J Exp Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00109-009-0457-0","article-title":"IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not.","volume":"87","author":"Wolk","year":"2009","journal-title":"J Mol Med (Berl)."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells.","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01771-2","article-title":"Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis.","volume":"8","author":"Al-Mossawi","year":"2017","journal-title":"Nat Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/annrheumdis-2016-209454","article-title":"A20 inhibition of STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesitis.","volume":"76","author":"De Wilde","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4110\/in.2013.13.6.257","article-title":"CP-690550 treatment ameliorates established disease and provides long-term therapeutic effects in an SKG arthritis model.","volume":"13","author":"Oh","year":"2013","journal-title":"Immune Netw."},{"key":"B22","article-title":"Blockade of the JAK\/STAT pathway inhibits inflammation and bone formation in two murine models of spondyloarthritis.","author":"Maeda","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34026-1","article-title":"Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases.","volume":"8","author":"Hammitzsch","year":"2018","journal-title":"Sci Rep."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1582-3","article-title":"IL-17A induces osteoblast differentiation by activating JAK2\/STAT3 in ankylosing spondylitis.","volume":"20","author":"Jo","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay4447","article-title":"JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function.","volume":"12","author":"Adam","year":"2020","journal-title":"Sci Transl Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis.","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis.","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial.","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors.","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis.","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis.","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease.","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis.","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis.","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial.","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial.","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjd.13745","article-title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an oral janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study.","volume":"12","author":"Sands","year":"2018","journal-title":"J Crohns Colitis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis.","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","article-title":"Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis.","volume":"193","author":"Works","year":"2014","journal-title":"J Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial.","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.semarthrit.2018.10.019","article-title":"The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis.","volume":"48","author":"Baraliakos","year":"2019","journal-title":"Semin Arthritis Rheum."},{"key":"B54","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.2553","article-title":"THU0377: Impact of Filgotinib on structural lesions in the sacroiliac joints at 12 weeks in patients with active axial Spondyloarthritis: magnetic resonance imaging data from the double-blind, randomized TORTUGA trial.","author":"Maksymowych","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B57","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.1723","article-title":"FRI0123: Safety profile of Baricitinib for the treatment of Rheumatoid Arthritis up to 8.4 years: an updated integrated safety analysis.","author":"Genovese","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B58","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.2396","article-title":"THU0187: Safety profile of Upadacitinib up to 3 years of exposure in patients with Rheumatoid Arthritis.","author":"Cohen","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001095","article-title":"Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.","volume":"6","author":"Harigai","year":"2020","journal-title":"RMD Open."},{"key":"B61","article-title":"THU0385: Safety of Tofacitinib therapy in HBsAG carriers with ankylosing spondylitis: a prospective study.","author":"Fang","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/14740338.2020.1743263","article-title":"The safety of baricitinib in patients with rheumatoid arthritis.","volume":"19","author":"Honda","year":"2020","journal-title":"Expert Opin Drug Saf."},{"key":"B63","article-title":"Infection events in Japanese patients with rheumatoid arthritis treated with tofacitinib: interim all-case post-marketing surveillance.","author":"Tamura","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy.","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B65","article-title":"FRI0164 Incidence rate and characterization of herpes zoster in patients with moderate-to-severe Rheumatoid Arthritis: an update from Baricitinib clinical studies.","author":"Chen","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B66","article-title":"THU0202: Integrated safety analysis of Filgotinib treatment for Rheumatoid Arthritis from 7 clinical trials.","author":"Genovese","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B67","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.2074","article-title":"THU0067: JAK selectivity and the impact on cytokine signaling inhibition at clinical Rheumatoid Arthritis doses.","author":"Gonzalez-Traves","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis.","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion.","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science."},{"key":"B70","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10067-014-2492-7","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis.","volume":"33","author":"Ungprasert","year":"2014","journal-title":"Clin Rheumatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/annrheumdis-2016-209315","article-title":"Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?","volume":"76","author":"Eriksson","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1315-z","article-title":"Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study.","volume":"19","author":"Bengtsson","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B73","article-title":"16L: Incidence of thromboembolic events in the Tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programs.","author":"Mease","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B74","year":"2020","journal-title":"FDA.gov."},{"key":"B75","year":"2020","journal-title":"emea.europa.eu."},{"key":"B76","article-title":"2358: Short-term risk of major adverse cardiovascular events or venous thrombo-embolic events in patients with rheumatoid arthritis initiating a janus kinase inhibitor: a meta-analysis of randomised controlled trials.","author":"Malaurie","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B77","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.2823","article-title":"OP0237: Thrombembolic safety profile of Tofacitinib and Baricitinib: an analysis of WHO VigiBase.","author":"Vallejo-Yag\u00fce","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments.","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"ITC65","DOI":"10.7326\/AITC201805010","article-title":"Acute colonic diverticulitis.","volume":"168","author":"Swanson","year":"2018","journal-title":"Ann Intern Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol."},{"key":"B81","year":"2020","journal-title":"accessdata.fda.gov."},{"key":"B82","year":"2020","journal-title":"pi.lilly.com."},{"key":"B83","year":"2020","journal-title":"pfizer.com."},{"key":"B84","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis.","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf."},{"key":"B85","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.msard.2019.08.006","article-title":"Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: report of two clinical cases.","volume":"35","author":"Cortese","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B87","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis.","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.591176\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T17:22:19Z","timestamp":1617988939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.591176\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2020.591176"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.591176","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"article-number":"591176"}}